AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04867369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 20mL 0.5%
Description: Interscalene nerve block with 20 mL 0.5% bupivacaine.
Study NCT04867369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 20mL 0.25%
Description: Pecs II fascial plane block with 20 mL 0.25% bupivacaine.
Study NCT04867369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine up to 15mL 0.25%
Description: Local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL.
Study NCT06636981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort2: ATRA+Toripalimab+TPC
Description: Receive 200 mg D1 of Toripalimab via intravenous infusion for a course of 21 days; TPC regimen (monoclonal antibody 10mg/kg D1, 8 intravenous infusions, 1 course of treatment every 21 days; Elibulin 1.4mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Utideron 40mg/m2 D1-5 intravenous infusions, 1 course of treatment every 21 days; Gemcitabine 1000mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Albumin paclitaxel 100 mg/m2 D1, D8, intravenous infusion, 1 course of treatment every 21 days); Capecitabine 1000mg/m2, D1-14, oral, one course of treatment every 21 days); All trans retinoic acid 20 mg bid, orally, D-3-D11, administered continuously for 14 days, stopped for 7 days, with one course of treatment lasting 21 days.
Study NCT06636981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort1: ATRA+Toripalimab+chemo
Description: Receive 200 mg of Toripalimab via D1 intravenous infusion, with 21 days as one course of treatment; Albumin paclitaxel 100 mg/m2, D1, D8, intravenous infusion, one course of treatment for 21 days; All trans retinoic acid 20 mg bid, oral, D-3-D11, continuous administration for 14 days, cessation for 7 days, 21 days is one course of treatment.
Study NCT06427980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal formula HuoXue LiShui
Description: The intervention consists of the oral administration of granule with either HXLS or a placebo substance, one bag (28.5 g) twice daily after meals for a period of 8 weeks. The granules are produced from four Chinese herbal pieces: Yi Mu Cao (Leonuri Herbal, 15.0g), Zhi Shui Zhi (Hirudo, 1.5g), Tao Ren (Semen persicae, 6.0g), and Hong Hua (Carthami Flos, 6.0g).
Study NCT06427980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese Herbal formula Placebo
Description: The placebo will be consistent with the HXLS oral granules in appearance, taste, and weight, to the greatest extent possible. In terms of outer packing, the HXLS and placebo granules will be exactly the same. It included Hu Jing (28.5g)
Study NCT06540339 — intervention group
Intervention type: OTHER
Intervention: Snapshot-audit studies do not necessitate any intervention in the defined cohorts.
Description: Snapshot-audit studies do not necessitate any intervention in the defined cohorts.
Study NCT05398809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib (Jakafi) is approved by the FDA for the treatment of intermediate or high-risk myelofibrosis in adults, polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea, and acute and chronic graft-versus-host disease in adult and pediatric patients (aged =12 years).
Study NCT05442593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training
Description: Participants will perform: 8 sets of 10 maximal countermovement jumps
Study NCT06329544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: 12-day isocaloric weight-maintaining high fructose diet (25% total calories from added fructose)
Study NCT06329544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose
Description: 12-day isocaloric weight-maintaining high glucose diet (25% total calories from added glucose)
Study NCT06042270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Betaine
Description: 3 grams per day for \~4 weeks
Study NCT06042270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 grams per day for \~4 weeks
Study NCT06600815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preemptive stepwise infiltration anaesthesia(PSIA)
Description: For PSIA patients, the anaesthetic is administered in stages. Initially, CA is injected at the incision site before the medial parapatellar incision. Following skin incision, more CA is injected into the subcutaneous tissue. After exposing the fascial layer and joint capsule, CA is used around the patellar tendon, and then CB is injected into the joint capsule and surrounding muscles. Additional CB is applied to the synovium and soft tissues after the joint cavity is opened, and more is used in the posterior joint capsule after bone resection.
Study NCT06600815 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postoperative local infiltration analgesia(PLIA)
Description: Before standardized TKA and implantation of the prosthesis, 30-40 mL of CB will be used to infiltrate the synovium and whole joint capsule. Subsequently, the joint cavity, subcutaneous tissue, and skin will be closed layer by layer using routine procedures. After the skin is closed, 30-40 mL of CA will be injected into the skin and subcutaneous tissue.
Study NCT06324188 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early atrial fibrillation ablation
Description: Patients randomised to early atrial fibrillation ablation will undergo pulmonary vein isolation within 2 months after randomisation.
Study NCT06324188 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care will consist of optimal AF therapy based on guideline recommendations and local protocols and usage.The choice of therapies and medications follows routine care in line with medical guidelines and local policies at the discretion of the treating physician and should be based on the individual medical status of each study patient.
Study NCT06611657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antirotinib hydrochloride
Description: Oral antirotinib treatment was started 2 weeks before radiotherapy for brain metastases, stopped for 1 week after 2 weeks, and continued after radiotherapy until tumor progression
Study NCT06274892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote monitoring PROs
Description: Attendance at RT review appointments triaged based on remotely monitored PROs
Study NCT06719596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium Bifidum Oral Capsule
Description: enteral nutrition+Pre-operative + one week post-operative Oral Bifidobacterium bifidum live triple capsule, 4 capsules Oral BID
Study NCT06721052 — intervention group
Intervention type: DRUG
Intervention: meta-Peng block
Description: The convex transducer was positioned obliquely in a superolateral to inferomedial direction just above the femoral crest. Anatomical structures including AIIS, iliopubic eminence, sartorius muscle, iliopsoas muscle, psoas tendon, artery, vein, and iliac fascia were identified sono-anatomically. The AIIS was centered in the transducer image. To determine the insertion point of the rectus femoris tendon (RFT) on the AIIS, the transducer was rotated sagittally, and the level where the RFT ends cephalically was identified. After identifying the target, the transducer was obliquated again to visualize the IPE. The 22G x 100 mm block needle was advanced in-plane from lateral to inferomedial towards the potential space between the IPM and AIIS. After confirming the target plane with a few mL of saline, 30-40 mL of 0.25% bupivacain was applied to the area. The spread of injectate was observed beneath the IPM, below the psoas tendon, and around the iliacus muscle within the iliac fascia.
Study NCT06721052 — intervention group
Intervention type: DRUG
Intervention: Postoperative analgesia management
Description: We ordered 400 mg intravenous ibuprofen for the patients every 8 hours during the postoperative period. We planned to perform 100 mg tramadol as a rescue analgesic if the patient's NRS score was above 4. We observed the patients for 24 hours in the postoperative period.
Study NCT05152706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Cycling at the aerobic intensity
Study NCT05152706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photons therapy
Study NCT05294328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine+Brimonidine combination ophthalmic solution
Description: LNZ101-combination ophthalmic solution
Study NCT05294328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine ophthalmic solution
Description: LNZ100- aceclidine ophthalmic solution
Study NCT05294328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Proprietary Ophthalmic Solution
Description: Proprietary Vehicle Ophthalmic Solution
Study NCT05488002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical intervention
Description: Pharmacists will provide clinical recommendations to patients allocated to the intervention group. Furthermore, they will monitor patients' parameters and follow-up with them. These interventions include daily medication review, weight, heart monitoring, blood glucose level, follow-up on medication adherence, and even mental status.
Study NCT04936035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by SC injection
Study NCT04936035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered by SC injection
Study NCT04936035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALN-AGT01
Description: ALN-AGT01 administered by SC injection
Study NCT04936035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-AGT01
Description: ALN-AGT01 administered by SC injection
Study NCT06482996 — intervention group
Intervention type: OTHER
Intervention: Intraocular pressure (IOP) was measured
Description: The Frail Scale was used to assess the frailty of the patients.Intraocular pressure (IOP) was measured before anesthesia, 5 minutes after induction of anesthesia and 1 hour postoperatively. IOP was measured using a Tono-pen tonometer (AccuPen). The normal range of IOP is 11-21 mmHg (mean 16 mmHg) and values above 24 mmHg are pathologic.
Study NCT06331884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AK1967 (Procizumab)
Description: DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)
Study NCT06331884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of placebo
Study NCT05894824 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: T-Dxd(Trastuzmab deruxtecan), Ramucirumab
Description: Phase Ib will use a standard 3+3 scheme with the planned doses of T-DXd (4.4\~6.4 mg/kg) once every 3 weeks in combination with Ramucirumab 8mg/kg administered once every 2 weeks.~* Dosing Regimen~  * Trastruzumab deruxtecan : One IV infusion every 3 weeks on Day 1 of each 21-day cycle~ * Ramucirumab : One IV infusion on every 2 weeks on Day 1,15 of each 28-day cycle
Study NCT05462626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic Occupational Performance Empowerment (HOPE) Lifestyle Program
Description: The intervention is comprised of the following sessions and themes; Session 1: Informed Consent and Pre-Testing; Session 2: Occupation and Healthy Aging; Session 3: Longevity and Thriving; Session 4: Movement Matters; Session 5: Thoughtful Eating; Session 6: Stress and Sleep; Session 7: Navigating Health Care; Session 8: Post-Testing and Discharge.
Study NCT04665037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole IV 6 mg/kg
Description: POS 6 mg/kg body weight by IV infusion
Study NCT04665037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole PFS 6 mg/kg
Description: POS nominal 6 mg/kg body weight based on weight bands taken orally
Study NCT05178316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP150
Description: Oral administration of JZP150 once daily in the morning
Study NCT05178316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo once daily in the morning
Study NCT04848870 — intervention group
Intervention type: OTHER
Intervention: Salivary samples
Description: collection of salivary samples from Sjögren patients on routine care in the oral medicine department.NA
Study NCT06048783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program of systematic and periodic spiritual accompaniment and care
Description: Systematic and periodic spiritual accompaniment and care
Study NCT06183541 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pericapsular Nerve Group (PENG) Block
Description: Pericapsular nerve group (PENG) block The femoral nerve and obturator nerve terminal branches, which provide sensory innervation of the hip joint, are blocked, thus providing analgesia without creating a motor block.
Study NCT06183541 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular Nerve Group (PENG) Block
Description: Pericapsular nerve group (PENG) block The femoral nerve and obturator nerve terminal branches, which provide sensory innervation of the hip joint, are blocked, thus providing analgesia without creating a motor block.
Study NCT05732922 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants to use during their telemedicine consultations with health care providers.
Description: A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants in the intervention arm to use during their telemedicine consultations with health care providers.
Study NCT06324123 — intervention group
Intervention type: OTHER
Intervention: Peacetil
Description: Nutraceutical supplement Peacetil for a period of 2 months
Study NCT05865106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-based speech therapy
Description: Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.
Study NCT05865106 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional speech therapy
Description: Participants will receive treatment maintaining the same frequency as the intervention group.
Study NCT05677971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fazirsiran Injection
Description: Participants will receive fazirsiran 200 mg/ml SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
Study NCT05677971 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo (sterile normal saline \[0.9% NaCl\]) SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
Study NCT05596045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC10
Description: Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
Study NCT05596045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to receive placebo
Study NCT05962242 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: External Beam Radiation to Head and Neck
Study NCT05754450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVTX-803
Description: L-fucose crystalline powder
Study NCT05666076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular nerve block
Description: The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.
Study NCT05666076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprascapular nerve block
Description: The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.
Study NCT05666076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and prilocaine hydrochloride
Description: The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
Study NCT05666076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and prilocaine hydrochloride
Description: The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
Study NCT04913012 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Systematic aerobic training
Description: Two-three weekly supervised aerobic exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
Study NCT04913012 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Systematic aerobic training
Description: Two-three weekly supervised aerobic exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
Study NCT04913012 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Systematic resistance training
Description: Two-three weekly supervised resistance exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
Study NCT04913012 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Systematic resistance training
Description: Two-three weekly supervised resistance exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
Study NCT04913012 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aerobic training booster sessions
Description: Supervised aerobic training booster sessions delivered in the follow up period (two sessions every fifth week).
Study NCT04913012 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Resistance training booster sessions
Description: Supervised resistance training booster sessions in the follow up period (two sessions every fifth week).
Study NCT06302010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Ball Intervention
Description: The stress ball has a soft plastic or silicone structure that can be held comfortably. Each ball is approximately 6 cm in diameter, in different colors, and is a soft toy that can be squeezed and manipulated with fingers to relieve stress and muscle tension and exercise the muscles (Apaydin Cirik et al., 2023). Squeezing a stress ball is a distraction and relaxation method. It is thought that squeezing a stress ball may be advantageous for reducing anxiety, considering its reliability, easy accessibility, effectiveness, low cost, sustainability, non-pharmacological and non-invasive properties.
Study NCT04765657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inclisiran sodium
Description: Subcutaneously injected on Day 1, 90 and 270 (Core Part). Subcutaneously injected on Day 360 and every 6 months thereafter until EOS visit (Extension Part)
Study NCT04765657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously injected on Day 1, 90, and 270.
Study NCT06045754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion.
Study NCT06045754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab subcutaneous injection.
Study NCT06045754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab intravenous infusion.
Study NCT06045754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab subcutaneous injection.
Study NCT05300282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): Atezolizumab will not be administered. In phase II b study - arm B (experimental): Atezolizumab will be administered at MTD determined in phase I study plus BEGEV regimen (at dosages performed by local practice).
Study NCT05300282 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BEGEV
Description: In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): only BEGEV will be administered. In phase II b study - arm B (experimental): BEGEV regimen will be administered in combination with Atezolizumab at MTD determined in phase I.
Study NCT05300282 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BEGEV
Description: In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): only BEGEV will be administered. In phase II b study - arm B (experimental): BEGEV regimen will be administered in combination with Atezolizumab at MTD determined in phase I.
Study NCT05735119 — intervention group
Intervention type: DEVICE
Intervention: Tapestry Biointegrative Implant
Description: Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.